High Court's Myriad Ruling Won't Crush Biotech Industry

By Jeff Overley (June 13, 2013, 10:10 PM EDT) -- The U.S. Supreme Court's ruling Thursday invalidating Myriad Genetics Inc.'s patents on isolated human genes won't deal a serious financial blow to the biotechnology industry, and could even strengthen it by allowing intellectual property protections for synthetic DNA and giving scientists greater leeway to experiment with genetic material, experts say....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!